Evofem Biosciences Files 8-K with Material Agreements & Equity Sales
Ticker: EVFM · Form: 8-K · Filed: Oct 3, 2024 · CIK: 1618835
Sentiment: neutral
Topics: material-agreement, debt-obligation, equity-sale, financials
TL;DR
Evofem dropped an 8-K: new deals, debt acceleration, equity sales, and financials filed. Big moves happening.
AI Summary
Evofem Biosciences, Inc. announced on September 27, 2024, that it entered into a Material Definitive Agreement. The company also reported triggering events that accelerate or increase a direct financial obligation or an obligation under an off-balance sheet arrangement. Additionally, Evofem Biosciences disclosed unregistered sales of equity securities and filed financial statements and exhibits.
Why It Matters
This 8-K filing indicates significant corporate actions, including new agreements and potential financial obligations, which could impact the company's financial health and stock performance.
Risk Assessment
Risk Level: medium — The filing details material agreements, potential financial obligations, and unregistered equity sales, all of which carry inherent risks for investors.
Key Players & Entities
- Evofem Biosciences, Inc. (company) — Registrant
- September 27, 2024 (date) — Date of earliest event reported
FAQ
What specific Material Definitive Agreement was entered into by Evofem Biosciences?
The filing does not specify the details of the Material Definitive Agreement, only that one was entered into on or before September 27, 2024.
What are the triggering events that accelerate or increase financial obligations?
The filing mentions these triggering events but does not provide specific details about what they are or the exact nature of the accelerated or increased obligations.
When were the unregistered sales of equity securities made?
The filing indicates that unregistered sales of equity securities occurred, but the specific date or details of these sales are not provided in the summary information.
What financial statements and exhibits were filed?
The filing states that financial statements and exhibits were filed, but the specific content of these documents is not detailed in the provided summary.
What was Evofem Biosciences' former company name?
Evofem Biosciences, Inc. was formerly known as Neothetics, Inc., with a date of name change on September 5, 2014.
Filing Stats: 1,534 words · 6 min read · ~5 pages · Grade level 12.4 · Accepted 2024-10-03 16:36:56
Key Financial Figures
- $0.0001 — ch registered Common stock, par value $0.0001 per share EVFM OTCQB Indicate by
- $460,000 — ed") for an aggregate purchase price of $460,000. The powers, preferences, rights, quali
- $106.8 million — e price would be equal to approximately $106.8 million. Pursuant to Section 5.7(b) of the SPA,
Filing Documents
- form8-k.htm (8-K) — 52KB
- ex2-1.htm (EX-2.1) — 25KB
- ex10-1.htm (EX-10.1) — 288KB
- ex10-2.htm (EX-10.2) — 221KB
- 0001493152-24-039392.txt ( ) — 871KB
- evfm-20240927.xsd (EX-101.SCH) — 3KB
- evfm-20240927_lab.xml (EX-101.LAB) — 33KB
- evfm-20240927_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. EVOFEM BIOSCIENCES, INC. Dated: October 3, 2024 By: /s/ Saundra Pelletier Saundra Pelletier Chief Executive Officer